Email Alert RSS
Volume 9 Issue 3
. 
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2018  >  9(3): 193-196
Zhi-lei CHEN, Feng-chun ZHANG. Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001
Citation: Zhi-lei CHEN, Feng-chun ZHANG. Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001
shu

Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention

doi: 10.3969/j.issn.1674-9081.2018.03.001
  • 1.

    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: ZHANG Feng-Chun Tel: 010-69155007, E-mail: Zhangfccra@aliyun.com
  • Received Date: 2018-05-03
  • Publish Date: 2018-05-30
    Abstract
  • Connective tissue disease (CTD) is a group of systemic disorder characterized by autoimmunity and autoimmune-mediated organ and system damage. The pulmonary complication is an important extra-articular feature of CTD and a major cause of mortality. The key point in the management of CTD-associated interstitial lung disease (CTD-ILD) should focus on the type of ILD, the stage of the disease, and what proper measures should be taken. CTD-ILD is still using the classification of idiopathic interstitial pneumonia. However, there is no authoritative clinical guidance for the diagnosis and treatment of CTD-ILD. More and more studies show that some auto-antibodies are strongly associated with CTD-ILD, which may guide clinical practice. In clinical practice, physicians should particularly pay more attention to CTD patients with insignificant pulmonary manifestations, so as to identify CTD-ILD in the early stage and intervene at the right time to delay the progression.
    • FullText(HTML)
  • loading
    • References(21)
  • [1] Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement:update on the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2013, 188:733-748. doi:  10.1164/rccm.201308-1483ST
    [2] Wells AU, Denton CP. Interstitial lung disease in connective tissue disease-mechanisms and management[J]. Nat Rev Rheumatol, 2014, 10:728-739. doi:  10.1038/nrrheum.2014.149
    [3] 张奉春.弥漫性结缔组织病的肺间质病变[J].中华临床免疫和变态反应杂志, 2008, 2:171-172. doi:  10.3969/j.issn.1673-8705.2008.03.001
    [4] Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome[J]. Am J Respir Crit Care Med, 2002, 165:1581-1586. doi:  10.1164/rccm.2106012
    [5] Ueda T, Sakagami T, Kikuchi T, et al. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis[J]. Respir Investig, 2018, 56:14-20. doi:  10.1016/j.resinv.2017.11.004
    [6] Karampitsakos T, Tzouvelekis A, Chrysikos S, et al. Pulmonary hypertension in patients with interstitial lung disease[J]. Pulm Pharmacol Ther, 2018, pii: S1094-5539(17)30242-0. http://www.sciencedirect.com/science/article/pii/S1094553917302420
    [7] Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis results from an inception cohort[J]. Rheumatology (Oxford), 2010, 49:1483-1489. doi:  10.1093/rheumatology/keq035
    [8] Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relation to outcome[J]. Eur Respir J, 2011, 37:1411-1417. doi:  10.1183/09031936.00019210
    [9] Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis[J]. Ann Rheum Dis, 2004, 63:297-301. doi:  10.1136/ard.2003.006122
    [10] Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyo-sitis-dermatomyositis-associated interstitial lung disease[J]. Am J Respir Crit Care Med, 2001, 164:1182-1185. doi:  10.1164/ajrccm.164.7.2103110
    [11] Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome[J]. Chest, 2006, 130:1489-1495. doi:  10.1378/chest.130.5.1489
    [12] Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome:a clinical, radiologic, and pathologic study[J]. Am J Respir Crit Care Med, 2005, 171:632-638. doi:  10.1164/rccm.200403-417OC
    [13] Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVⅢ:factors predictive of pulmonary damage[J]. Lupus, 2007, 16:410-417. doi:  10.1177/0961203307079042
    [14] Swigris JJ, Fischer A, Gillis J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus[J]. Chest, 2008, 133:271-280. doi:  10.1378/chest.07-0079
    [15] Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease[J]. Expert Rev Clin Immunol, 2016, 12:509-520. doi:  10.1586/1744666X.2016.1139454
    [16] Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis[J]. Rheumatology, 2016, 55:1906-1910. doi:  10.1093/rheumatology/kew224
    [17] Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis[J]. Lung, 2009, 187:201-206. doi:  10.1007/s00408-009-9146-6
    [18] Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab[J]. Rheumatology (Oxford), 2010, 49:1013. doi:  10.1093/rheumatology/kep438
    [19] Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders[J]. Lancet, 2012, 380:689-698. doi:  10.1016/S0140-6736(12)61079-4
    [20] Bonella F, Costabel U. Biomarkers in connective tissue disease associated interstitial lung disease[J]. Semin Respir Crit Care Med, 2014, 35:181-200. doi:  10.1055/s-0034-1371527
    [21] 张亚妹, 彭清林, 卢昕, 等.抗PUF60抗体在中国特发性炎性肌病患者中的分布及临床意义[J].协和医学杂志, 2017, 4:244-250. doi:  10.3969/j.issn.1674-9081.2017.05.010
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (409) PDF downloads(328) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return